# | Title | Journal | Year | Citations |
---|
1 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Lancet, The | 2018 | 3,542 |
2 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Lancet, The | 2017 | 3,224 |
3 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 2,771 |
4 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1,816 |
5 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
6 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | Lancet Oncology, The | 2020 | 1,363 |
7 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial | Journal of Clinical Oncology | 2020 | 1,255 |
8 | Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma | New England Journal of Medicine | 2018 | 1,253 |
9 | Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma | JAMA Oncology | 2016 | 1,192 |
10 | High performance plasma amyloid-β biomarkers for Alzheimer’s disease | Nature | 2018 | 1,180 |
11 | High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast Material | Radiology | 2014 | 1,112 |
12 | The Chemokine Superfamily Revisited | Immunity | 2012 | 914 |
13 | Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial | Lancet, The | 2017 | 753 |
14 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
15 | Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer | JAMA Oncology | 2018 | 735 |
16 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma | Journal of Clinical Oncology | 2020 | 723 |
17 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Lancet Oncology, The | 2014 | 678 |
18 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC | Nature | 2021 | 649 |
19 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 568 |
20 | CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study | Lancet Oncology, The | 2013 | 555 |
21 | Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial | Lancet, The | 2022 | 537 |
22 | IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer | British Journal of Cancer | 2015 | 533 |
23 | Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study | Lancet Oncology, The | 2016 | 533 |
24 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial | Lancet Oncology, The | 2022 | 526 |
25 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) | Annals of Oncology | 2019 | 512 |
26 | A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX | Journal of Bone and Mineral Research | 2016 | 508 |
27 | Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus: Second Edition | Neurologia Medico-Chirurgica | 2012 | 506 |
28 | Diagnosis and management of Guillain–Barré syndrome in ten steps | Nature Reviews Neurology | 2019 | 463 |
29 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer | JAMA Oncology | 2020 | 446 |
30 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 418 |
31 | Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial | Gut | 2020 | 411 |
32 | Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis | Annals of Neurology | 2014 | 405 |
33 | Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 398 |
34 | Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society | Esophagus | 2015 | 383 |
35 | Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection | Journal of Hepatology | 2018 | 360 |
36 | Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial | Journal of Thoracic and Cardiovascular Surgery | 2019 | 347 |
37 | Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015 | Journal of Hepato-Biliary-Pancreatic Sciences | 2015 | 332 |
38 | Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05) | Japanese Journal of Clinical Oncology | 2019 | 329 |
39 | JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome | Circulation Journal | 2019 | 324 |
40 | CCR4 and its ligands: from bench to bedside | International Immunology | 2015 | 314 |
41 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | Journal of Hepatology | 2020 | 310 |
42 | Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity | Clinical Cancer Research | 2016 | 309 |
43 | Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update | Liver Cancer | 2021 | 307 |
44 | Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy | Cancer Science | 2016 | 305 |
45 | Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | | 2022 | 298 |
46 | Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary | Archives of Osteoporosis | 2012 | 284 |
47 | Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer | Annals of Oncology | 2013 | 284 |
48 | Outcomes for out-of-hospital cardiac arrests across 7 countries in Asia: The Pan Asian Resuscitation Outcomes Study (PAROS) | Resuscitation | 2015 | 279 |
49 | Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome | Circulation Journal | 2014 | 277 |
50 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer | Journal of Thoracic Oncology | 2021 | 274 |